Cleveland Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>CB</div>
CBLI -- USA Stock  

USD 1.90  0.08  4.04%

The stock goes through an active upward rally. Cleveland BioLabs Enterprise Value is most likely to decrease significantly in the upcoming years. The preceding year's Enterprise Value was reported at 5.31 Million. The current Market Capitalization is estimated to increase to about 7 M, while Net Income Per Employee is projected to decrease to (103 K). While some baby boomers are getting worried about healthcare space, it is reasonable to concentrate on Cleveland BioLabs as an investment alternative.
Published over two weeks ago
View all stories for Cleveland BioLabs | View All Stories
How much will Cleveland BioLabs owe in October?
The current Long Term Debt to Equity is estimated to decrease to 0.0138. The current Debt to Equity Ratio is estimated to decrease to -0.28The company has a current ratio of 5.07, suggesting that it is liquid enough and is able to pay its financial obligations when due. The company has Profit Margin (PM) of (246.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (213.98) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.14.
Cleveland BioLabs financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Cleveland BioLabs, including all of Cleveland BioLabs's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Cleveland BioLabs assets, the company is considered highly leveraged. Understanding the composition and structure of overall Cleveland BioLabs debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Cleveland Total Debt

Cleveland BioLabs liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Cleveland BioLabs has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Cleveland BioLabs balance sheet include debt obligations and money owed to different Cleveland BioLabs vendors, workers, and loan providers. Below is the chart of Cleveland main long-term debt accounts currently reported on its balance sheet.
You can use Cleveland BioLabs financial leverage analysis tool to get a better grip on understanding its financial position

How important is Cleveland BioLabs's Liquidity

Cleveland BioLabs financial leverage refers to using borrowed capital as a funding source to finance Cleveland BioLabs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cleveland BioLabs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cleveland BioLabs's total debt and its cash.

Sale by Yakov Kogan of 300 shares of Cleveland BioLabs

Legal trades by Cleveland BioLabs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cleveland BioLabs insider trading alert for sale of common stock by Yakov Kogan, COO Secretary, on 28th of April 2020. This event was filed by Cleveland Biolabs Inc with SEC on 2010-02-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Cleveland BioLabs Investor Appetite?

Cleveland BioLabs reported the previous year's revenue of 857.83 K. Net Loss for the year was (2.12 M) with loss before overhead, payroll, taxes, and interest of (543.01 K).

Liabilities Breakdown

Total Liabilities1.08 Million
Current Liabilities1.08 Million
Long-Term Liabilities7,813.45

Will Cleveland BioLabs growth be justifiable after the rise?

The maximum drawdown is down to 190.16 as of today. Cleveland BioLabs is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Cleveland BioLabs implied risk.

Our Conclusion on Cleveland BioLabs

While few other entities under the biotechnology industry are still a bit expensive, Cleveland BioLabs may offer a potential longer-term growth to stockholders. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to exit some or all of your Cleveland BioLabs holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cleveland BioLabs.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Cleveland BioLabs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com